COVID-19

SARS-CoV-2

One 60mg tablet P.O. once per day for 14 days

Pyridostigmine Bromide

Placebo

Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

Pyridostigmine in Severe SARS-CoV-2 Infection

Pyridostigmine in Patients With Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2 Infection

Composite of death, Need for mechanical ventilation, or an increase of 2 or more points in the SOFA score

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

Participants will receive pyridostigmine at a dose of 60 mg / day (or matching placebo), P.O. during a period of up to 14 days, until hospital discharge, death, mechanical ventilation, or increase in the SOFA scale ≥2 points.
The proposed dose is a safe dose according to the experience in myasthenia gravis and healthy people, as well as in at least three clinical studies in people living with HIV.
Participants will be double-blind 1: 1 randomized to receive pyridostigmine or placebo for up to 14 days.

Sugammadex for reversal of steroidal neuromuscular blockers, intravenous injection ,2mg/kg

Reversal of neuromuscular blockers, iv injection, 0.05 mg/kg

Post-operative Residual Curarization

Sugammadex Injection [Bridion]

Neostigmine

Different Reversal Agents in Pediatric Day-case Cancer Surgery

Sugammadex Versus Neostigmine in Pediatric Day-case Cancer Surgery

time from neostigmine or sugammadex administration until recovery of the TOF ratio to 0.9%

time from neuromuscular blocker administration to extubation

Amani Gaber Mohamed,MSc

Senior registra

National Cancer Institute, Egypt

Traumatic Brain Injury

Each parotid salivary gland will be injected with 75MU of Botulinum Toxin type-A, 0.15mls in total, with 0.09mls into the mass of the gland and another 0.06mls into the adjacent part above the masseter muscle, using a 1ml syringe and a 30 gauge needle.
Each submandibular salivary gland will be injected with 15MU of Botulinum Toxin A, administering 0.03mls, using a 1ml syringe and a 30 gauge needle.

Botulinum Toxin

The Wellington Hospital

Botulinum Toxin and Saliva Management in Tracheotomised Patients

A Randomised Placebo Controlled Trial to Explore the Effectiveness of Botulinum Toxin Injection at Reducing Oral Secretions and Frequency of Tracheal Suctioning in Tracheotomised Patients.

sialorrhea/hypoxia

Pyridostigmine in Severe SARS-CoV-2 Infection

Different Reversal Agents in Pediatric Day-case Cancer Surgery

Botulinum Toxin and Saliva Management in Tracheotomised Patients

O mais completo banco de dados de ervas medicinais apoiado pela ciência